HMG / Menopur: Direct Gonadotropin Therapy
Last updated: March 2026
Human Menopausal Gonadotropin (HMG/Menopur) provides direct FSH and LH activity — bypassing the hypothalamus and pituitary entirely. The only fertility drug that delivers both gonadotropins simultaneously, making it the gold standard for spermatogenesis induction and ovarian stimulation in hypogonadotropic patients.
FSH + LH Activity
From Azoospermia
SC or IM Injection
📋 On this page
How HMG Works
HMG bypasses the entire hypothalamic-pituitary axis and delivers FSH and LH directly to their target organs — the gonads. This makes it uniquely effective for patients whose pituitary cannot produce adequate gonadotropins, regardless of why.
The FSH component of HMG binds FSH receptors on ovarian granulosa cells (women) and testicular Sertoli cells (men). In women, this drives follicular development and estrogen production. In men, FSH activates Sertoli cells — the "nurse cells" of sperm — initiating and supporting spermatogenesis and maintaining the blood-testis barrier.
The LH component binds LH receptors on testicular Leydig cells (men) and ovarian theca cells (women). In men, LH stimulates intratesticular testosterone production — essential for spermatogenesis since sperm maturation requires testosterone concentrations 50–100× higher than serum. This dual FSH+LH action gives HMG advantages over FSH-only products for male fertility.
In men with hypogonadotropic hypogonadism (Kallmann syndrome, pituitary damage, post-steroid suppression), HMG combined with hCG provides the complete FSH+LH stimulus needed to initiate de novo spermatogenesis. The process takes 6–24 months — matching the ~74-day spermatogenic cycle. Early FSH priming may predict faster recovery.
In women, HMG drives multifollicular development for IVF or controlled ovarian stimulation for IUI. Studies suggest HMG may produce better oocyte quality than recombinant FSH alone due to the LH component supporting theca cell androgen production — a substrate for follicular estrogen synthesis. This may translate to improved embryo quality and live birth rates in certain patient populations.
What the Clinical Trials Show
Data from hypogonadotropic hypogonadism spermatogenesis trials and IVF stimulation studies.
Side Effects & Risks
Key Takeaways
- HMG provides direct FSH + LH activity — bypasses pituitary entirely
- ~68% of azoospermic men with hypogonadotropic hypogonadism achieve sperm presence after HMG therapy
- Dual FSH+LH action offers potential advantages over FSH-only products for male fertility
- 75–150 IU SC/IM 3x/week is standard for male spermatogenesis induction
- FDA-approved for female ovarian stimulation (Menopur, Repronex)
- Spermatogenesis induction requires 6–24 months — patience is mandatory
- Optimal HMG vs. recombinant FSH + recombinant LH combination for IVF
- Long-term sperm quality outcomes after HMG-induced spermatogenesis
- Whether early FSH priming before hCG treatment truly accelerates recovery
- Head-to-head comparisons across different HMG formulations (urinary vs. highly-purified)
🛒 Recommended Products
Monitoring and injection supplies for HMG fertility protocols.
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational purposes only. It is not medical advice. HMG preparations (Menopur, Repronex) are prescription drugs that must only be used under the supervision of a licensed reproductive endocrinologist or fertility specialist. Ovarian monitoring via ultrasound and blood tests is mandatory during female stimulation to prevent ovarian hyperstimulation syndrome. Never self-administer fertility medications without medical supervision.